96-57-1

Usage

Uses

Used in Dye and Pigment Production:
N,N-dimethyl-2-nitrotoluene-4-sulphonamide is utilized as an intermediate in the synthesis of various dyes and pigments due to its unique molecular structure and chemical properties.
Used in Pharmaceutical Industry:
N,N-dimethyl-2-nitrotoluene-4-sulphonamide is used as a starting material or intermediate in the development of pharmaceuticals, taking advantage of its chemical reactivity and potential medicinal properties.
Used as Antifungal and Antibacterial Agent:
Due to its potential medicinal properties, N,N-dimethyl-2-nitrotoluene-4-sulphonamide has been explored as a potential antifungal and antibacterial agent, although its toxic nature requires careful handling and further research for safe application.
It is important to handle N,N-dimethyl-2-nitrotoluene-4-sulphonamide with care, as it is considered toxic and may cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C9H12N2O4S/c1-7-4-5-8(6-9(7)11(12)13)16(14,15)10(2)3/h4-6H,1-3H3

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 616-83-1 4-methyl-3-nitrobenzenesulfonyl chloride 
• 124-40-3 dimethyl amine 

Downstream Products

• 955978-68-4 3-bromo-4,N,N-trimethyl-3-nitro-benzenesulfonamide 
• 1303574-30-2 C₁₂H₁₄N₂O₇S 
• 955978-71-9 3-bromo-4-(2-dimethylamino-vinyl)-N,N'-dimethyl-5-nitro-benzenesulfonamide 
• 149913-85-9 α-phenyl-2-amino-4-(N,N-dimethylsulfamoyl)phenethyl alcohol 
• 149913-94-0 6-(N,N-dimethylsulfamoyl)-2-phenylindole 
• 149913-81-5 α-phenyl-4-(N,N-dimethylsufamoyl)-2-nitrophenethyl alcohol 

Relevant academic research and scientific papers

Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5

N-Hydroxyindole-2-carboxylates possessing sulfonamide-substituents at either position 5 or 6 were designed and synthesized. The inhibitory activities of these compounds against isoforms 1 and 5 of human lactate dehydrogenase were analysed, and Ki values of the most efficient inhibitors were determined by standard enzyme kinetic studies. Some of these compounds displayed state-of-the-art inhibitory potencies against isoform 5 (Ki values as low as 5.6 μM) and behaved as competitive inhibitors versus both the substrate and the cofactor.

THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS

Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS

The invention provides compounds which are pyrimidines of formula (I) wherein R1 is a group -NR-(CHR)m-X; R2 is a substituted indolyl group; R is H or C1-C6 alkyl; m is 1, 2, 3 or 4; and X is a pyridyl ring; and the pharmaceutically acceptable salts thereof. These compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PHARMACEUTICAL COMPOUNDS

The invention provides compounds which are pyrimidines of formula (I): wherein R2 is bonded at ring position 2 and -YR1 is bonded at ring position 5 or 6, or YR1 is bonded at ring position 2 and R2 is bonded at ring position 6; R is an indol-4-yl group which is substituted at the 5- or 6-position; either: (a) Y is selected from -O-(CH2)n-, -NH-(CH2)n-,. -NHC(O)-(CH2)n and -C(O)NH-(CH2)n- wherein n is 0 or an integer of 1 to 3, and R1 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted and a group -NR3R4 wherein R3 and R4, which are the same or different, are each independently selected from H, C1-C6 alkyl which is unsubstituted or substituted, C3 - C10 cycloalkyl which is unsubstituted or substituted, -C(O)R, -C(O)N(R)2 and -S(O)mR, or R3 and R4 together form, with the nitrogen atom to which they are attached, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted; (b) Y is a direct bond and R1 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted, and a group -NR3R4 wherein R3 and R4, which are the same or different, are each independently selected from H, C1-C6 alkyl which is unsubstituted or substituted, C3-C10 cycloalkyl which is unsubstituted or substituted, -C(O)R, -C(O)N(R)2 and -S(O)mR; R is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, which group is unsubstituted or substituted; and m is 1 or 2; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PO K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PB kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound which is a pyrimidine of formula (I): The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS

Thienopyrimidines of formula (Ia) or (Ib): wherein R1, R2, R3, are as defined in the claims.